|
1
|
Maas JW, Groothuis PG, Dunselman GA, de
Goeij AF, Struyker Boudier HA and Evers JL: Endometrial
angiogenesis throughout the human menstrual cycle. Hum Reprod.
16:1557–1561. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Uz YH, Murk W, Yetkin CE, Kayisli UA and
Arici A: Expression and role of interleukin-23 in human endometrium
throughout the menstrual cycle and early pregnancy. J Reprod
Immunol. 87:21–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Latif F, Tory K, Gnarra J, Yao M, Duh FM,
Orcutt ML, Stackhouse T, Kuzmin I, Modi W and Geil L:
Identification of the von Hippel-Lindau disease tumor suppressor
gene. Science. 260:1317–1320. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kamada M, Suzuki K, Kato Y, Okuda H and
Shuin T: von Hippel-Lindau protein promotes the assembly of actin
and vinculin and inhibits cell motility. Cancer Res. 61:4184–4189.
2001.PubMed/NCBI
|
|
5
|
Lonser RR, Glenn GM, Walther M, Chew EY,
Libutti SK, Linehan WM and Oldfield EH: von Hippel-Lindau disease.
Lancet. 361:2059–2067. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pavlova TV, Kashuba VI, Muravenko OV,
Yenamandra SP, Ivanova TA, Zabarovskaia VI, Rakhmanaliev ER,
Petrenko LA, Pronina IV, Loginov VI, Iurkevich OIu, Kiselev LL,
Zelenin AV and Zabarovskiĭ ER: Technology of analysis of
epigenetic and structural changes of epithelial tumors genome with
NotI-microarrays by the example of human chromosome. Mol Biol
(Mosk). 43:339–347. 2009.(In Russian).
|
|
7
|
Osada R, Horiuchi A, Kikuchi N, Yoshida J,
Hayashi A, Ota M, Katsuyama Y, Mellilo G and Konishi I: Expression
of hypoxia-inducible factor 1α, hypoxia-inducible factor 2α, and
von Hippel-Lindau protein in epithelial ovarian neoplasms and
allelic loss of von Hippel-Lindau gene: nuclear expression of
hypoxia-inducible factor 1α is an independent prognostic factor in
ovarian carcinoma. Hum Pathol. 38:1310–1320. 2007.
|
|
8
|
Choi CH, Lee KM, Choi JJ, Kim TJ, Kim WY,
Lee JW, Lee SJ, Lee JH, Bae DS and Kim BG: Hypermethylation and
loss of heterozygosity of tumor suppressor genes on chromosome 3p
in cervical cancer. Cancer Lett. 255:26–33. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kaelin WG Jr: The von Hippel-Lindau tumor
suppressor protein and clear cell renal carcinoma. Clin Cancer Res.
13:680s–684s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kamada M, Suzuki K, Kato Y, Okuda H and
Shuin T: von Hippel-Lindau protein promotes the assembly of actin
and vinculin and inhibits cell motility. Cancer Res. 61:4184–4189.
2001.PubMed/NCBI
|
|
11
|
Noyes RW, Herting A and Rock J: Dating the
endometrial biopsy. Am J Obstet Gynecol. 122:262–263.
1975.PubMed/NCBI
|
|
12
|
Richards FM, Schofield PN, Fleming S and
Maher ER: Expression of the von Hippel-Lindau disease tumour
suppressor gene during human embryogenesis. Hum Mol Genet.
5:639–644. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang N, Mack F, Haase VH, Simon MC and
Johnson RS: pVHL function is essential for endothelial
extracellular matrix deposition. Mol Cell Biol. 26:2519–2530. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu JY, Zhu WJ, Cao XZ, Li XF and Wu J:
Aberrant expression of the von Hippel-Lindau gene in human
endometrial hyperplasia and endometrial carcinoma. Int J Gynecol
Cancer. 21:430–434. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rajakumar A, Doty K, Daftary A, Markovic N
and Conrad KP: Expression of von Hippel Lindau (pVHL) protein in
placentae from normal pregnant women and women with preeclampsia.
Placenta. 27:411–421. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Datta K, Mondal S, Sinha S, Li J, Wang E,
Knebelmann B, Karumanchi SA and Mukhopadhyay D: Role of
elongin-binding domain of von Hippel Lindau gene product on
HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma.
Oncogene. 24:7850–7858. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Choueiri TK, Vaziri SA, Jaeger E, Elson P,
Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan
AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM and
Ganapathi R: von Hippel-Lindau gene status and response to vascular
endothelial growth factor targeted therapy for metastatic clear
cell renal cell carcinoma. J Urol. 180:860–865. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nayak NR and Brenner RM: Vascular
proliferation and vascular endothelial growth factor expression in
the rhesus macaque endometrium. J Clin Endocrinol Metab.
87:1845–1855. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Critchley HO, Osei J, Henderson TA,
Boswell L, Sales KJ, Jabbour HN and Hirani N: Hypoxia-inducible
factor-1α expression in human endometrium and its regulation by
prostaglandin E-series prostanoid receptor 2 (EP2). Endocrinology.
147:744–753. 2006.
|
|
20
|
André H and Pereira TS: Identification of
an alternative mechanism of degradation of the hypoxia-inducible
factor-1α. J Biol Chem. 283:29375–29384. 2008.
|
|
21
|
Genbacev O, Krtolica A, Kaelin W and
Fisher SJ: Human cytotrophoblast expression of the von
Hippel-Lindau protein is downregulated during uterine invasion in
situ and upregulated by hypoxia in vitro. Dev Biol. 233:526–536.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaloglu C and Onarlioglu B: Extracellular
matrix remodelling in rat endometrium during early pregnancy: the
role of fibronectin and laminin. Tissue Cell. 42:301–306. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Z, Kreiner M, van der Walle CF and
Mardon HJ: Clustered integrin α5β1 ligand displays model
fibronectin-mediated adhesion of human endometrial stromal cells.
Biochem Biophys Res Commun. 407:777–782. 2011.
|
|
24
|
Zhou Q, Pardo A, Königshoff M, Eickelberg
O, Budinger GR, Thavarajah K, Gottardi CJ, Jones J, Varga J, Selman
M, Sznajder JI, Raj JU and Zhou G: Role of von Hippel-Lindau
protein in fibroblast proliferation and fibrosis. FASEB J.
25:3032–3044. 2011. View Article : Google Scholar : PubMed/NCBI
|
